The 3 case-control studies by Drs Rahme, Solomon, Watson, and their colleagues1- 3 published recently in the ARCHIVES suggest that the main reason for an increased risk of MI found for rofecoxib when compared with naproxen in the Vioxx Gastrointestinal Outcomes Research (VIGOR) trial4 may be a cardioprotective effect of naproxen. We have 2 concerns with this interpretation.
Jüni P, Dieppe P, Egger M. Risk of Myocardial Infarction Associated With Selective COX-2 Inhibitors: Questions Remain. Arch Intern Med. 2002;162(22):2639. doi: